New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:08 EDTRHHBY, HALORoche filing triggers $4M milestone payment to Halozyme
Halozyme Therapeutics (HALO) announced that Roche (RHHBY) has submitted a line extension application to the European Medicines Agency for a subcutaneous, SC, formulation of MabThera® (rituxumab). The filing of the application triggered a $4M milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche.
News For HALO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 5, 2015
13:58 EDTRHHBYSome European stocks still look appealing amid Greek uncertainty, Barron's says
Subscribe for More Information
July 1, 2015
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 22, 2015
07:45 EDTHALOHalozyme price target raised to $25 from $20 at JPMorgan
JPMorgan raised its price target for Halozyme to $25 after speaking with CEO Hellen Torley. The firm remains positive on the potential for PEGPH20 and keeps an Overweight rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use